Loxo Oncology Inc.
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
Last updated:
Abstract:
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Status:
Grant
Type:
Utility
Filling date:
27 Aug 2018
Issue date:
3 Sep 2019